

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **March 18, 2019**

**HARROW HEALTH, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-35814**  
(Commission  
File Number)

**45-0567010**  
(IRS Employer  
Identification No.)

**12264 El Camino Real, Suite 350**  
**San Diego, CA**  
(Address of principal executive offices)

**92130**  
(Zip Code)

Registrant's telephone number, including area code: **(858) 704-4040**

**N/A**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
- 
-

**Item 7.01. Regulation FD Disclosure**

Attached as Exhibit 99.1 to this Item 7.01 is a presentation of Harrow Health, Inc. (the “Company”), that is being used by the management of the Company at investor conferences and at meetings describing the Company.

The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits****(d) Exhibits**

<u>Item</u>	<u>Description</u>
-------------	--------------------

99.1	<a href="#">Harrow Health, Inc. Corporate Presentation dated March 2019</a>
------	---

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**HARROW HEALTH, INC.**

Dated: March 18, 2019

By: /s/ Andrew R. Boll

Name: Andrew R. Boll

Title: Chief Financial Officer

---





NASDAQ: HROW  
MARCH 2019

---

## SAFE HARBOR

This presentation contains express "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from Harrow Health, Inc.'s (the "Company" or "Harrow") expectations and projections. Some of these risks and uncertainties include, but are not limited to: the Company's ability to make commercially available its formulations and technologies in a timely manner or at all; market acceptance of the Company's formulations and challenges related to the marketing of the Company's formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn and raise additional funds when necessary; its ability to generate profits from sales of its formulations; risks related to research and development activities; its estimates of the current and potential market size for its technologies and formulations; unexpected data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at [www.sec.gov](http://www.sec.gov). This presentation may refer to non-GAAP financial metrics, specifically adjusted EBITDA and/or adjusted earnings. A reconciliation of any non-GAAP measures with the most directly comparable GAAP measures are included in the Company's press releases, available on its website. All forward-looking statements are qualified in their entirety by this cautionary statement. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Harrow expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. Our compounded formulations are not FDA approved. All trademarks, service marks and trade names included in this presentation are the property of their respective owners.



# Harrow Health Introduction

---

## VISION

- Mitigate investment risk of drug development for the benefit of shareholders and patients

## VALUE CREATION

- We *found* pharmaceutical companies
- We *finance* them
- We *own*:
  - large **equity stakes**, and
  - **royalties** on many of the drug candidates they develop

# Harrow Health Introduction



\* Pursuing a deconsolidating transaction  
\*\* Includes all future label extensions



# FINANCIAL METRICS



# Consolidated Financials

## TRENDS

### Revenue Growth:


- \$100M rev run rate goal in 2021
- 123% revenue CAGR 2014-2018
- Consolidated revenue grew 55% from 2017-2018
- Q3-Q4 2018 ophthalmology organic revenue growth of 12%
- New ophthalmology product launches expected in 2019

### Gross Margins:

- Continued expansion, hit 64% in Q4-2018, an all-time high
- Medium-term (2020-21) Gross margin targets of  $\geq 70\%$


### Profitability:

- Adjusted earnings expected in the second half of 2019



# Equity Portfolio

## HARROW'S DECONSOLIDATED EQUITY PORTFOLIO ESTIMATED VALUE: \$56M (NON-GAAP)\*



\*Melt and Surface equity values are estimated and based on the conversion price of Series A preferred stock – their most recently completed financing, which is not a U.S. GAAP measure. Eton value is calculated based on the closing stock market price of Eton's common stock as of Mar. 12, 2019



# Royalty Rights Portfolio

	DRUG CANDIDATE	PROPOSED INDICATION	MARKET OPPORTUNITY	CLINICAL STAGE	ROYALTY RATE
<b>ETON</b>	CT-100	INFANTILE SPASMS, RHEUMATOID ARTHRITIS	\$1.1B+ (Acthar® Gel '17 sales)	PRE-CLINICAL	6%
<b>SURFACE</b>	SURF-100	CHRONIC DRY EYE	\$1.5B+ (Restasis®/ Xiidra® '17 sales)	EXPECT PHASE II DATA IN 2020	4%
	SURF-200, 201	EPISODIC DRY EYE	\$1B + (Comp: Kala Pharma)	EXPECT PHASE II DATA IN 2020	4%
	SURF-300, 301	REFRACTORY DRY EYE	\$1B+	EXPECT PHASE II DATA IN 2020	6%
<b>MELT</b>	MELT-100	CONSCIOUS SEDATION	\$1B+ (Up to 100M U.S. uses annually <sup>2-12</sup> )	PHASE III DATA EXPECTED IN 2020/21	UP TO 8%
<b>MAYFIELD</b>	MAY-66	PEYRONIE'S DISEASE	Up to -95,000 U.S. men diagnosed annually <sup>1</sup>	PRE-CLINICAL	N/A
	MAY-88	INTERSTITIAL CYSTITIS	Up to -12% of U.S. women affected <sup>3</sup>		
<b>RADLEY</b>	RAD-100, 101 RAD-200 RAD-300	RARE DISEASES/ORPHAN INDICATIONS	N/A	PRE-CLINICAL	N/A




# **SUMMARY**

---



# Harrow Health Project 15



Management incentivized to achieve \$15 stock price

**LEG 1**

- Pharmaceutical compounding business is fast growing and cash-flowing

**LEG 2**

- Equity positions in deconsolidated businesses are now valued at ~\$56M\* (Non-GAAP)

**LEG 3**

- Future stream of royalties in diverse portfolio of drug development candidates

**FUTURE "LEGS"**

- Other 505(b)(1) and 505(b)(2) projects being evaluated



\*Melt and Surface equity values are estimated and based on the conversion price of Series A preferred stock - their most recently completed financing, which is not a U.S. GAAP measure.  
Eton value is calculated based on the closing stock market price of Eton's common stock as of March 12, 2019.

# **APPENDIX AND REFERENCES**

---



# References

1. Harrow Health internal business data, including IMS data, 2015-2019, and proprietary surveys, 2015-2019
2. Market Scope, LLC, Comprehensive Report on the Global IOL Market (2013, May).
3. Allen, A. (2007). Vasectomy Risks and Benefits. Retrieved November 08, 2016, from <http://www.webmd.com/men/features/vasectomy-risks-benefits>
4. US Market Report Suite for Gastrointestinal Endoscopic Devices 2017 – MedSuite. (2016, August 01). Retrieved January 08, 2017, from <https://datasearch.com/product/us-market-report-suite-for-gastrointestinal-endoscopic-devices-2017-medsuite/>
5. Endodontic Facts by the American Association of Endodontists. (n.d.). Retrieved January 07, 2017, from <http://www.aae.org/about-aae/newsroom/endodontic-facts.aspx>
6. Sklavos, M. M., Spracklen, C. N., Saftlas, A. F., & Pinto, L. A. (2014, February 23). Does Loop Electrosurgical Excision Procedure of the Uterine Cervix Affect Anti-Müllerian Hormone Levels? Retrieved January 08, 2017, from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953513/> and Centers for Disease Control and Prevention -United States, 2013. (2016, November 24). Retrieved January 07, 2017, from <https://www.cdc.gov/mmwr/volumes/65/ss/ss6512a1.htm>
7. Voigt, J., & Mosier, M. (2013, September). A powered bone marrow biopsy system versus manual methods: a systematic review and meta-analysis of randomised trials. Retrieved January 08, 2017, from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756462/>
8. Internal estimate based on data from National Hospital Ambulatory Medical Care Survey: 2015 Emergency Department Summary Tables [https://www.cdc.gov/nchs/data/nhamcs/web\\_tables/2015\\_ed\\_web\\_tables.pdf](https://www.cdc.gov/nchs/data/nhamcs/web_tables/2015_ed_web_tables.pdf)
9. ASPS 2015 Plastic Surgery Statistics Report - American Society of Plastic Surgeons. (2015). Retrieved January 8, 2017, from <https://d2wirczt3b6wjm.cloudfront.net/News/Statistics/2015/plastic-surgery-statistics-full-report-2015.pdf>
10. Internal estimate based on data from S. Amin (2015) ; Trends in Fracture Incidence: A Population-Based Study over 20 Years <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929546/>
11. IMV Medical Information Division, Inc. Benchmark Report MR2013 (2013, July). Retrieved December 15, 2016.
12. LaPointe. Bunion Surgery: A Prospective Clinical Outcomes Study; [http://www.podiatryinstitute.com/pdfs/Update\\_2001/2001\\_11.pdf](http://www.podiatryinstitute.com/pdfs/Update_2001/2001_11.pdf)
13. Centers for Disease Control and Prevention - United States. (2015, January). Retrieved February 27, 2019, from <https://www.cdc.gov/ic/index.html>



# Published Clinical Data

**Kindle, Trevor, MD, et al. (2018, January). Safety and efficacy of intravitreal injection of steroid and antibiotics in the setting of cataract surgery and trabecular microbypass stent. Journal of Cataract and Refractive Surgery.**

In a study of 483 eyes undergoing cataract surgery with concomitant trabecular microbypass stent insertion, there were no statistically significant differences in the safety profiles of a study group of 234 eyes receiving an intravitreal injection (pars plana) of 0.2mL of Droplless® at the time of surgery compared to a control group of 249 eyes that received a standard topical regimen postoperatively. To measure safety, intraocular pressure was recorded as were cases of inflammation, cystoid macular edema, infection, or retinal detachments.

**Lindstrom, R.L., et al. (2017, February). Droplless Cataract Surgery: An Overview. Current Pharmaceutical Design.**

Compliance issues are diminished with Droplless Therapy compared to standard post-surgery topical drop regimens. Cost savings to patients can range from \$200 to \$600 per cataract procedure. Staff time is reduced without patient, insurance and pharmacy callbacks about eye drop substitutions and confusion over topical regimens. A retrospective review of Droplless Therapy cases found no postoperative endophthalmitis. Post-surgery infection and inflammation rates were similar to reported rates with other alternative prophylactic therapies, such as topical drops.

**Tyson, S. L., et al. (2017, January). Clinical outcomes after injection of a compounded pharmaceutical for prophylaxis after cataract surgery: a large-scale review. Current Opinion in Ophthalmology.**

No major intraoperative complications associated with the transzonular injection technique. There were no cases of postoperative endophthalmitis. Rates of infection and inflammation reported in this retrospective review of 1,541 cases from 922 patients receiving a transzonular injection of Tri-Moxi-Vanc for prophylaxis after cataract surgery appear similar to reported rates with alternative prophylactic therapies such as topical drops.

**Fisher, B. L., & Potvin, R, (2016, July 18). Transzonular vitreous injection vs a single drop compounded topical pharmaceutical regimen after cataract surgery. Current Pharmaceutical Design.**

Review of the rationale for reducing topical therapy in cataract surgery prophylaxis, and what is known to date about the efficacy and safety of the Droplless approach. Both groups expressed similar satisfaction with surgery, but patients who received Droplless preferred the overall experience (P=0.01).



12264 EL CAMINO REAL, SUITE 350  
SAN DIEGO, CA 92130  
(858) 704-4040

[IR@HARROWINC.COM](mailto:IR@HARROWINC.COM)  
[WWW.HARROWINC.COM](http://WWW.HARROWINC.COM)

